1. HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma
- Author
-
Zhaoqiang Jiang, Yanbin Wang, Shibo Ying, and Jianing Yan
- Subjects
Mesothelioma ,0301 basic medicine ,Lung Neoplasms ,Clinical Biochemistry ,Inflammation ,chemical and pharmacologic phenomena ,Review Article ,HMGB1 ,Proinflammatory cytokine ,03 medical and health sciences ,0302 clinical medicine ,In vivo ,Biomarkers, Tumor ,Genetics ,Animals ,Humans ,Medicine ,HMGB1 Protein ,Molecular Biology ,Carcinogen ,lcsh:R5-920 ,biology ,business.industry ,Mesothelioma, Malignant ,Biochemistry (medical) ,Cancer ,General Medicine ,medicine.disease ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Biomarker (medicine) ,medicine.symptom ,business ,lcsh:Medicine (General) - Abstract
Malignant mesothelioma (MM) is a rare, aggressive, and highly lethal cancer that is substantially induced by exposure to asbestos fibers. High-mobility group box 1 (HMGB1) is an intriguing proinflammatory molecule involved in MM. In this review, we describe the possible crucial roles of HMGB1 in carcinogenic mechanisms based on in vivo and in vitro experimental evidence and outline the clinical findings of epidemiological investigations regarding the possible roles of HMGB1 as a biomarker for MM. We conclude that novel strategies targeting HMGB1 may suppress MM cells and interfere with asbestos-induced inflammation.
- Published
- 2019